Abstract

Tissue metalloproteinase inhibitors (MPTIs) play an important role in the pathogenesis of breast cancer (BC). Although recent studies have shown the dual role of MPTIs in the development of this pathology, it has been proven that they inhibit the activity of metalloproteinases prevent invasiveness and tumor recurrence. Conducting extensive research towards studying the antitumor effect of these protease inhibitors, especially MPTI-1, may allow the development of new drugs for the treatment of breast cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call